Results 71 to 80 of about 6,269,394 (372)

NEMA NU 2-2007 performance characteristics of GE Signa integrated PET/MR for different PET isotopes [PDF]

open access: yes, 2019
BackgroundFully integrated PET/MR systems are being used frequently in clinical research and routine. National Electrical Manufacturers Association (NEMA) characterization of these systems is generally done with F-18 which is clinically the most relevant
D'Asseler, Yves   +5 more
core   +1 more source

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status

open access: yesTheranostics, 2015
Prostate cancer (PCa) is the most common malignancy in men worldwide, leading to substantial morbidity and mortality. At present, imaging of PCa has become increasingly important for staging, restaging, and treatment selection.
S. Lütje   +9 more
semanticscholar   +1 more source

The application of radionuclide therapy for breast cancer

open access: yesFrontiers in Nuclear Medicine
Radionuclide-mediated diagnosis and therapy have emerged as effective and low-risk approaches to treating breast cancer. Compared to traditional anatomic imaging techniques, diagnostic radionuclide-based molecular imaging systems exhibit much greater ...
Anna Musket   +9 more
doaj   +1 more source

Nanohybrid of Silver‐MXene: A Promising Sorbent for Iodine Gas Capture from Nuclear Waste

open access: yesAdvanced Materials Interfaces, EarlyView.
Silver‐MXene (Ag‐Ti3C2Tx) nanohybrids effectively captured iodine gas at 150 °C, with Ag nanoparticles loaded onto MXene via silver nitrate reduction. Upon exposure to iodine gas, silver iodide forms, confirming successful adsorption. Ag‐Ti3C2Tx shows superior iodine uptake (946 mg g−1) compared to conventional sorbents, demonstrating its potential as ...
Karamullah Eisawi   +7 more
wiley   +1 more source

Evaluation of radiological and clinical efficacy of ^{90}Y-DOTATATE} therapy in patients with progressive metastatic midgut neuroendocrine carcinomas [PDF]

open access: yes, 2009
Background: To evaluate the radiological and clinical therapeutic effectiveness of ^{90}Y-octreotate [DOTATATE] inpatients with progressive somatostatin receptor-positive midgut neuroendocrine carcinomas (GEPNETs).
Buscombe, John R.   +7 more
core  

99mTc-DTPA and 131I-hippuran findings in liver transplant recipients treated with cyclosporin A. [PDF]

open access: yes, 1982
The effects of cyclosporin A (CyA), an immunosuppressive agent that is potentially nephrotoxic, on the kidneys of 9 liver transplant recipients were studied with serial 99mTc-DTPA and 131I-hippuran scans.
Iwatsuki, S   +4 more
core   +1 more source

Chlorotoxin peptide-functionalized polyethylenimine-entrapped gold nanoparticles for glioma SPECT/CT imaging and radionuclide therapy

open access: yesJournal of Nanobiotechnology, 2019
BackgroundMalignant glioma is the most common and deadliest brain cancer due to the obstacle from indistinct tumor margins for surgical excision and blood brain barrier (BBB) for chemotherapy.
Lingzhou Zhao   +7 more
semanticscholar   +1 more source

A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89Zr/131I‐Labeled Tinurilimab

open access: yesAdvanced Science, EarlyView.
This study investigates the integrated diagnostic and therapeutic strategy utilizing 89Zr/131I‐labeled tinurilimab for the management of malignant lung nodules, with a particular focus on lung adenocarcinoma (LUAD). CEACAM6, which is highly expressed in most LUAD patients, activates the Src/FAK signaling pathway, thereby promoting cell proliferation ...
Chongyang Chen   +8 more
wiley   +1 more source

Early Diagnosis of Alzheimer's disease by NIRF Spectroscopy and Nuclear Medicine [PDF]

open access: yes, 2011
There is an urgent need for the early detection of diseases such as Alzheimer’s (AD) and Cancers in order to enable their successful treatment. Cancer is the second major cause of death after Heart Disease, and AD is the third major cause of death
I. C. Baianu
core   +1 more source

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years

open access: yesWorld Journal of Nuclear Medicine, 2020
In recent years, lutetium-177 (177Lu)-labeled prostate-specific membrane antigen (PSMA)-617 has become a promising new therapeutic agent in patients with metastatic castration-resistant prostate cancer (mCRPC).
Majid Assadi   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy